Mesoblast Limited Stock OTC Markets
Stocks
MEOBF
AU000000MSB8
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.700 USD | +9.68% |
|
+9.68% | -10.53% |
| 07-17 | ASX Biggest Losers | MT |
| 07-14 | Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial | MT |
| Market Cap | 3.17B 2.21B 1.93B 1.78B 1.64B 3.1B 213B 21.32B 8.38B 104B 8.31B 8.12B 359B | P/E 2026 * |
-39.2x | P/E 2027 * | 86.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3.14B 2.2B 1.92B 1.77B 1.63B 3.08B 211B 21.16B 8.32B 104B 8.25B 8.06B 356B | EV / Sales 2026 * |
17.4x | EV / Sales 2027 * | 9.82x |
| Free-Float |
64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Mesoblast Limited
| 1 day | +9.68% | ||
| 1 week | +9.68% | ||
| Current month | +9.68% | ||
| 1 month | +9.68% | ||
| 3 months | +6.25% | ||
| 6 months | +6.92% | ||
| Current year | -10.53% |
| 1 week | 1.7 |  | 1.7 |
| 1 month | 1.55 | | 1.7 |
| Current year | 1.55 | | 2.05 |
| 1 year | 1.35 | | 2.59 |
| 3 years | 0.1 | | 5.34 |
| 5 years | 0.1 | | 5.34 |
| 10 years | 0.01 | | 9.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Silviu Itescu
CEO | Chief Executive Officer | 69 | 23/03/2011 |
James O'Brien
DFI | Director of Finance/CFO | 59 | 17/11/2025 |
Teresa Montagut
CTO | Chief Tech/Sci/R&D Officer | - | 11/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Silviu Itescu
BRD | Director/Board Member | 69 | 01/01/2007 |
Eric Rose
BRD | Director/Board Member | 75 | 15/04/2013 |
William Burns
BRD | Director/Board Member | 78 | 06/03/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.68% | +9.68% | - | - | 2.21B | |
| -1.29% | -3.11% | -0.35% | +3.09% | 49.18B | |
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | |
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | |
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | |
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | |
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | |
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | |
| Average | +1.02% | +0.03% | +65.98% | +98.43% | 27.07B | |
| Weighted average by Cap. | +0.03% | -0.18% | +79.44% | +123.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 180M 126M 110M 101M 93.54M 176M 12.12B 1.21B 477M 5.94B 473M 462M 20.43B | 311M 217M 190M 175M 162M 304M 20.93B 2.09B 824M 10.25B 816M 798M 35.29B |
| Net income | -76.81M -53.63M -46.87M -43.25M -39.87M -75.14M -5.16B -517M -203M -2.53B -201M -197M -8.71B | 47.76M 33.35M 29.15M 26.9M 24.79M 46.73M 3.21B 321M 126M 1.57B 125M 123M 5.42B |
| Net Debt | -23.05M -16.09M -14.06M -12.98M -11.96M -22.55M -1.55B -155M -61.01M -759M -60.44M -59.11M -2.61B | -110M -76.47M -66.83M -61.67M -56.84M -107M -7.36B -737M -290M -3.61B -287M -281M -12.42B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/26 | $1.700 | +9.68% | 1,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MSB Stock
- MEOBF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
